A global genomic survey of Streptococcus pneumoniae has identified 621 strains across 50 countries and has highlighted how the bacteria can evolve in response to vaccination.
To round up 2018, we asked our Expert panel to choose their top papers from across the year. Here, you can discover the articles they selected and read about and the reasons why!
The US FDA has approved Paratek Pharmaceuticals’ antibiotic Nuzyra™ (omadacycline) for the treatments of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Merck’s antibiotic ZERBAXA® (ceftolozane and tazobactam) has met its primary endpoint of non-inferiority compared with meropenem in a Phase III trial of patients with hospital-acquired and ventilator-associated bacterial pneumonia.
An isolate of colistin-heteroresistant, carbapenem-resistant, hypervirulent/hypermucoviscous Klebsiella pneumoniae has been identified in the USA.
Could carbon monoxide be used to manage sepsis-related lung injury? – an interview with Bryan Kraft, MD
In this interview, we speak to Dr. Bryan Kraft, an Assistant Professor of Medicine at Duke University, about his research into carbon monoxide as a potential therapy to treat ARDS and the clinical trial for this therapy that is currently underway.
Comparison of Clinical & Laboratory Standards Institute standards in antimicrobial susceptibility among the carbapenemase producing Enterobacteriaceae
In this article, carbapenem antimicrobial susceptibility testing profiles were determined in a population of Klebsiella pneumoniae, and their resistance assessed based on previous and current Clinical and Laboratory Standards Institute criteria.
Green synthesis of capped gold nanoparticles and their effect on Gram-positive and Gram-negative bacteria
This research reports the synthesis of capped gold nanoparticles by reducing HAuCl4 with flower and leaf extracts of Ocimum tenuiflorum, leaves of Azadirachta indica and Mentha spicata and peel of Citrus sinensis plants and assessed their activity on Staphylococcus aureus, Pseudomonas aeruginosa and Klebsiella pneumoniae.
ST37 Klebsiella pneumoniae: development of carbapenem resistance in vivo during antimicrobial therapy in neonates
Currently, carbapenems are an antibiotic option against MDR K. pneumoniae worldwide, however, carbapenem resistance is being reported on a large scale. This study investigates the mechanism leading to in vivo carbapenem resistance development in Klebsiella pneumoniae.
Researchers demonstrate how one of the deadliest hospital-acquired infections can be prevented by training and culture-change interventions.